A randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma.
To assess the effectiveness of IV and nebulised magnesium sulphate in the treatment of acute severe asthma.
Multi centre randomised controlled trial of intravenous (IV) or nebulised magnesium sulphate versus placebo for acute severe asthma
Professor Steve Goodacre
Professor Alasdair Gray
S Goodacre, J Cohen, M Bradburn, A Gray, J Benger, T Coats on behalf of the 3Mg Research Team. The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for severe acute asthma. The Lancet Respiratory Medicine. (2013); 1:293 – 300.
Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, et al. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. . Health Technology Assessment. (2014);18(22).
Identification and characterization of the clinical toxicology of novel psychoactive substances (NPS) by laboratory analysis of biological samples from recreational drug users.
Identification of Novel Psychoactive Substances (IONA)
The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.
A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
Traumatic Brain Injury (TBI) is the leading cause of death and disabilities amongst young people worldwide. Many sufferers develop chronic physical and mental health problems and are unable to work or re-engage socially after their injuries. There are therefore significant health and socioeconomic consequences.
A study examining the Prevalence and Risk of Anterior Pituitary Dysfunction following Traumatic Brain Injury